STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS
The invention encompasses injectable therapeutic formulations for injection into patients in need thereof, wherein the injectable formulations are injected using a medical device having a hydrophobic surface; the injectable therapeutic formulation comprises a therapeutic protein and a stabilizing excipient that protects the therapeutic protein from forming particulates or aggregates in the presence of the hydrophobic surface. Also included are methods for reducing particulates or aggregates by using such injectable therapeutic formulations in medical devices having hydrophobic surfaces.
1 . An injectable therapeutic formulation for injection into a patient in need thereof using a medical device having a hydrophobic surface, wherein the injectable therapeutic formulation comprises a therapeutic protein and a stabilizing excipient that protects the therapeutic protein from forming particulates or aggregates in the presence of the hydrophobic surface.
2 . The injectable therapeutic formulation of claim 1 , wherein the medical device is a syringe.
3 . The injectable therapeutic formulation of claim 2 , wherein the syringe is lubricated with silicone oil.
4 . The injectable therapeutic formulation of claim 1 , wherein the hydrophobic surface is formed from a silicone-based material.
5 . The injectable therapeutic formulation of claim 1 , wherein the hydrophobic surface is coated with a silicone oil.
6 . The injectable therapeutic formulation of claim 1 , wherein the therapeutic protein is selected from the group consisting of an antibody, an antibody-drug conjugate, an enzyme, a cytokine, a neurotoxin, a fusion protein, an immunogenic protein, a PEGylated protein, and an antibody fragment.
7 - 11 . (canceled)
12 . The injectable therapeutic formulation of claim 1 , wherein the formulation contains at least 100 mg/mL of the therapeutic protein.
13 . (canceled)
14 . (canceled)
15 . The injectable therapeutic formulation of claim 1 , wherein the formulation contains at least about 1 to about 5000 ppm of the stabilizing excipient.
16 . (canceled)
17 . (canceled)
18 . The injectable therapeutic formulation of claim 1 , wherein the stabilizing excipient excludes polypropylene glycol block copolymers.
19 . The injectable therapeutic formulation of claim 18 , wherein the stabilizing excipient is selected from the group consisting of polypropylene glycol, adducts of polypropylene glycol, and random copolymers comprising propylene oxide units.
20 . The injectable therapeutic formulation of claim 19 , wherein the stabilizing excipient is a polypropylene glycol homopolymer.
21 - 31 . (canceled)
32 . The injectable therapeutic formulation of claim 1 , wherein the formulation further comprises a second stabilizing excipient.
33 - 37 . (canceled)
38 . The injectable therapeutic formulation of claim 1 , wherein the formation of particulates or aggregates is reduced as compared to that of a control formulation, wherein the control formulation is identical on a dry weight basis in every way to the therapeutic formulation except that it lacks the stabilizing excipient.
39 . (canceled)
40 . A method of reducing the formation of particulates or aggregates in a medical device having a hydrophobic surface and containing an injectable therapeutic formulation comprising a therapeutic protein, wherein the injectable therapeutic formulation contacts the hydrophobic surface and forms particulates or aggregates in contact therewith, the method comprising formulating the injectable therapeutic protein with a stabilizing excipient to produce the therapeutic formulation for use with the medical device, wherein the stabilizing excipient is added to the injectable therapeutic formulation in an amount sufficient to reduce the formation of particulates or aggregates.
41 . The method of claim 40 , wherein the hydrophobic surface comprises silicone.
42 . The method of claim 40 , wherein the hydrophobic surface is a surface coated with a silicone oil.
43 . The method of claim 40 , wherein the therapeutic protein is selected from the group consisting of an antibody, an antibody-drug conjugate, an enzyme, a cytokine, a neurotoxin, a fusion protein, an immunogenic protein, a PEGylated protein, and an antibody fragment.
44 . The method of claim 40 , wherein the stabilizing excipient is selected from the group consisting of polypropylene glycol, adducts of polypropylene glycol, and random copolymers comprising propylene oxide units.
45 . The method of claim 40 , wherein the formation of particulates or aggregates is reduced as compared to that of a control formulation, wherein the control formulation is identical on a dry weight basis in every way to the therapeutic formulation except that it lacks the stabilizing excipient.
46 - 52 . (canceled)